ALOXI for chemotherapy-induced nausea and vomiting (CINV)
ALOXI (palonosetron HCl) injection 0.25 mg is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, and acute nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy.
ALOXI is contraindicated in patients known to have hypersensitivity to the drug or any of its components. Most commonly reported adverse reactions include headache (9%) and constipation (5%).
ALOXI for postoperative nausea and vomiting (PONV)
ALOXI® (palonosetron HCl) injection 0.075 mg is indicated for the prevention of postoperative nausea and vomiting for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated.
ALOXI is contraindicated in patients known to have hypersensitivity to the drug or any of its components. Most commonly reported adverse reactions (incidence ?2%) include QT prolongation (5%), bradycardia (4%), headache (3%), and constipation (2%).